Illumina Inc. ($ILMN) Stock Forecast: Up 3.2% Today

What is Illumina Inc.?

Illumina (ILMN) is a global genomics leader, known for providing next-generation sequencing solutions across various markets. The stock had a strong bullish movement today amidst its participation in the 2025 China International Import Expo (CIIE) and recent positive share price performance.

Why is Illumina Inc. going up?

ILMN stock is up 3.2% on Dec 9, 2025 18:41

• The bullish movement of Illumina is linked to its active participation and partnerships at the 2025 CIIE, showcasing its commitment to the Chinese market and highlighting potential growth opportunities.
• The recent share price rebound and positive gains over 30 and 90 days indicate investor confidence in Illumina's future prospects, despite some fluctuations over the past year.
• Analysts' mixed views on Illumina's valuation suggest ongoing debates regarding the stock's pricing, with considerations around future growth expectations and cash flow trajectory influencing investor sentiment.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

Illumina at the 2025 China International Import Expo (CIIE)

Illumina showcased new technologies and formed partnerships at the 2025 China International Import Expo (CIIE), demonstrating its commitment to China's "In China, For China" strategy. The company is a global genomics leader, providing comprehensive next-generation sequencing solutions across various research, clinical, and applied markets. Illumina's innovative sequencing and array technologies are driving advancements in life science research, translational and consumer genomics, and molecular diagnostics.

https://www.illumina.com/company/video-hub/mbMsedlREQQ.html

Illumina (ILMN): Assessing Valuation After a Quiet Share Price Rebound

Illumina (ILMN) has seen a recent share price rebound, with a 5.33% gain over 30 days and 30.35% over 90 days, despite a negative 8.6% return over the past year. Analysts generally view the stock as slightly overvalued at $128.96 against a fair value of $119.84, while a Discounted Cash Flow (DCF) model suggests it could be undervalued at $156.27. The primary debate revolves around whether the current price anticipates future growth or if the stock is undervalued given its cash flow trajectory.

https://finance.yahoo.com/news/illumina-ilmn-assessing-valuation-quiet-021024016.html

Trending Today

Filecoin ($FIL) Crypto Forecast: Up 5.0% Today

PancakeSwap ($CAKE) Crypto Forecast: Down 5.1% Today

Silver ($XAG) Commodity Forecast: Up 5.0% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 5.7% Today

Comcast Corporation Class A Common Stock ($CMCSA) Stock Forecast: Up 5.0% Today

National Oilwell Varco Inc. ($NOV) Stock Forecast: Down 5.1% Today

Phillips 66 ($PSX) Stock Forecast: Down 5.1% Today

Pfizer Inc. ($PFE) Stock Forecast: Down 5.1% Today

Humana Inc. ($HUM) Stock Forecast: Down 5.1% Today

Cytokinetics, Incorporated ($CYTK) Stock Forecast: Down 5.0% Today

Illumina Inc. Price History

16.09.2025 - ILMN Stock was up 5.2%

• The reasons behind the bullish movement in ILMN stock are:
• Favorable comparisons with another stock, potentially positioning ILMN as the more valuable choice.
• Investors seeking promising opportunities in the market may have been attracted by this comparison, resulting in heightened buying activity for ILMN shares.
• Positive perceptions of ILMN's technology and competitive position compared to its rival could have spurred increased demand for the stock.

15.08.2025 - ILMN Stock was up 5.2%

• The bullish movement in ILMN stock today can be attributed to the positive market sentiment surrounding the launch of the Illumina Protein Prep Assay.
• The rollout of this new product is expected to enhance Illumina's capabilities in multiomics research, which could lead to significant advancements in understanding various diseases.
• Investors are likely optimistic about the potential revenue growth and market expansion opportunities that the Illumina Protein Prep Assay could bring to the company, driving the stock's upward trajectory.

01.07.2025 - ILMN Stock was down 10.2%

• Despite Illumina (ILMN) surpassing earnings and revenue estimates in Q2, the stock experienced a strong bearish movement.
• The market may have reacted negatively due to profit-taking by investors after a period of strong performance leading up to the earnings release.
• Additionally, there could be concerns about future growth prospects or guidance provided by the company that did not meet heightened market expectations.
• It's possible that some investors were expecting even better results, leading to a sell-off in the stock despite the positive earnings surprise.

01.07.2025 - ILMN Stock was down 8.7%

• Despite reporting better-than-expected earnings and revenues for the second quarter, Illumina's stock experienced a significant bearish movement.
• The market's reaction may have been influenced by profit-taking behaviors, potentially following a period of favorable outcomes, leading to a temporary decline in the stock price.
• The results slightly below some investors' expectations could have induced a sense of disappointment, contributing to the bearish sentiment in the market.
• Nevertheless, the observed bearish movement could be a brief response to the earnings report, and the long-term outlook for Illumina appears promising, given its strong position in the biotechnology sector.

05.10.2025 - ILMN Stock was up 5.3%

• Following the company's surpassing of its third-quarter guidance and the narrowing of its full-year revenue decline forecast, Illumina's stock rose by over 23%, indicating optimistic growth prospects.
• Investor sentiment towards Illumina turned positive, with notable investors showing confidence in the company's future performance.
• The third-quarter earnings report exceeded expectations, reporting adjusted earnings of $1.34 per share, surpassing consensus estimates and contributing to the stock's significant increase.
• Illumina's ability to outperform expectations in both earnings and revenue for the quarter ended September 2025 showcases robust operational performance and potential for further growth in the genomics sector.

08.09.2025 - ILMN Stock was down 5.5%

• The bearish movement in ILMN today could be attributed to profit-taking by investors after a period of strong performance.
• The upcoming earnings report, despite expectations of a beat, might have led to some uncertainty among investors, causing a sell-off.
• The partnership with pharma companies for CDx development is a positive long-term move, but short-term investors might be reacting cautiously to the news, contributing to the bearish trend.
• Overall, the bearish movement in ILMN today seems to be a short-term market correction rather than a reflection of the company's fundamentals.

06.07.2025 - ILMN Stock was down 5.4%

• The bearish movement in ILMN stock today can be attributed to the settlement with the Department of Justice (DOJ) and Veterans to end a whistleblower lawsuit, leading to a significant financial payout.
• Despite reporting better-than-expected earnings for the second quarter and surpassing revenue estimates, the negative impact of the settlement on the company's finances likely overshadowed the positive financial results.
• Investors may be concerned about the implications of the settlement on Illumina's reputation and future legal challenges, leading to a sell-off of the stock.
• The market reaction reflects the delicate balance between financial performance and legal risks in the biotechnology sector, highlighting the importance of maintaining regulatory compliance and ethical standards to sustain investor confidence.

31.09.2025 - ILMN Stock was up 14.2%

• Exceeded earnings and revenue expectations for the third quarter.
• Positive surprise indicates strong demand for its products and services.
• Investors are optimistic about its future outlook.
• Market's bullish movement on ILMN today could be attributed to strong financial performance and growth opportunities in the genomics industry.

31.09.2025 - ILMN Stock was up 23.9%

• Illumina's stock soared today following better-than-expected third-quarter earnings.
• The company reported adjusted earnings of $1.34 per share, exceeding the consensus of $1.17, which contributed to the bullish movement.
• Positive earnings and revenue surprises of +15.52% and +1.73%, respectively, for the quarter ended September 2025, further fueled investor confidence in Illumina's growth prospects.
• Overall, the strong financial performance and optimistic outlook from Illumina's earnings likely drove the bullish movement in the stock today.

31.09.2025 - ILMN Stock was up 25.0%

• Illumina's stock surged due to better-than-expected third-quarter earnings, with adjusted earnings surpassing consensus estimates.
• The bullish sentiment towards Illumina was further reinforced by deep-pocketed investors adopting a positive approach towards the company, as revealed by options trading data.
• The company's ability to beat both earnings and revenue estimates for the third quarter showcased its strong performance and potential for future growth, contributing to the stock's upward momentum.
• Overall, Illumina's impressive financial results and market sentiment drove the stock higher, indicating investor confidence in the company's strategic direction and growth prospects in the DNA sequencing industry.

09.11.2025 - ILMN Stock was up 3.2%

• The bullish movement of Illumina is linked to its active participation and partnerships at the 2025 CIIE, showcasing its commitment to the Chinese market and highlighting potential growth opportunities.
• The recent share price rebound and positive gains over 30 and 90 days indicate investor confidence in Illumina's future prospects, despite some fluctuations over the past year.
• Analysts' mixed views on Illumina's valuation suggest ongoing debates regarding the stock's pricing, with considerations around future growth expectations and cash flow trajectory influencing investor sentiment.

01.09.2025 - ILMN Stock was up 6.5%

• Illumina's bullish movement today could be attributed to positive comparisons highlighting its value and growth potential in the precision oncology and biomedical sectors.
• Positive assessments of Illumina's growth momentum and value compared to other companies in the industry may have sparked investor interest and contributed to the stock's upward trajectory.
• Investors may view Illumina as a strong contender in the precision medicine space, driving demand for the stock and fueling its bullish movement.